+1 347 708 0418
The Myasthenia Gravis Therapies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Myasthenia Gravis Therapies size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Myasthenia Gravis Therapies market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Myasthenia Gravis Therapies market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Ocular Myasthenia Gravis
Congenital Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Myasthenia Gravis
Others
Market segment by Application, can be divided into
Hospitals and Clinics
Diagnostic Centers
Academic and Research Organizations
Market segment by players, this report covers
Alexion Pharmaceuticals
Novartis
CSL Behring
Grifols
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Myasthenia Gravis Therapies
1.2 Classification of Myasthenia Gravis Therapies by Type
1.2.1 Overview: Global Myasthenia Gravis Therapies Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Myasthenia Gravis Therapies Revenue Market Share by Type in 2020
1.2.3 Ocular Myasthenia Gravis
1.2.4 Congenital Myasthenia Gravis
1.2.5 Generalized Myasthenia Gravis
1.2.6 Transient Myasthenia Gravis
1.2.7 Others
1.3 Global Myasthenia Gravis Therapies Market by Application
1.3.1 Overview: Global Myasthenia Gravis Therapies Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Centers
1.3.4 Academic and Research Organizations
1.4 Global Myasthenia Gravis Therapies Market Size & Forecast
1.5 Global Myasthenia Gravis Therapies Market Size and Forecast by Region
1.5.1 Global Myasthenia Gravis Therapies Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Myasthenia Gravis Therapies Market Size by Region, (2016-2021)
1.5.3 North America Myasthenia Gravis Therapies Market Size and Prospect (2016-2026)
1.5.4 Europe Myasthenia Gravis Therapies Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Myasthenia Gravis Therapies Market Size and Prospect (2016-2026)
1.5.6 South America Myasthenia Gravis Therapies Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Myasthenia Gravis Therapies Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Myasthenia Gravis Therapies Market Drivers
1.6.2 Myasthenia Gravis Therapies Market Restraints
1.6.3 Myasthenia Gravis Therapies Trends Analysis
2 Company Profiles
2.1 Alexion Pharmaceuticals
2.1.1 Alexion Pharmaceuticals Details
2.1.2 Alexion Pharmaceuticals Major Business
2.1.3 Alexion Pharmaceuticals Myasthenia Gravis Therapies Product and Solutions
2.1.4 Alexion Pharmaceuticals Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Alexion Pharmaceuticals Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Myasthenia Gravis Therapies Product and Solutions
2.2.4 Novartis Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Novartis Recent Developments and Future Plans
2.3 CSL Behring
2.3.1 CSL Behring Details
2.3.2 CSL Behring Major Business
2.3.3 CSL Behring Myasthenia Gravis Therapies Product and Solutions
2.3.4 CSL Behring Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 CSL Behring Recent Developments and Future Plans
2.4 Grifols
2.4.1 Grifols Details
2.4.2 Grifols Major Business
2.4.3 Grifols Myasthenia Gravis Therapies Product and Solutions
2.4.4 Grifols Myasthenia Gravis Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Grifols Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Myasthenia Gravis Therapies Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Myasthenia Gravis Therapies Players Market Share
3.2.2 Top 10 Myasthenia Gravis Therapies Players Market Share
3.2.3 Market Competition Trend
3.3 Myasthenia Gravis Therapies Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Myasthenia Gravis Therapies Revenue and Market Share by Type (2016-2021)
4.2 Global Myasthenia Gravis Therapies Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Myasthenia Gravis Therapies Revenue Market Share by Application (2016-2021)
5.2 Myasthenia Gravis Therapies Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Myasthenia Gravis Therapies Revenue by Type (2016-2026)
6.2 North America Myasthenia Gravis Therapies Revenue by Application (2016-2026)
6.3 North America Myasthenia Gravis Therapies Market Size by Country
6.3.1 North America Myasthenia Gravis Therapies Revenue by Country (2016-2026)
6.3.2 United States Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
6.3.3 Canada Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
6.3.4 Mexico Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Myasthenia Gravis Therapies Revenue by Type (2016-2026)
7.2 Europe Myasthenia Gravis Therapies Revenue by Application (2016-2026)
7.3 Europe Myasthenia Gravis Therapies Market Size by Country
7.3.1 Europe Myasthenia Gravis Therapies Revenue by Country (2016-2026)
7.3.2 Germany Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
7.3.3 France Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
7.3.5 Russia Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
7.3.6 Italy Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Myasthenia Gravis Therapies Revenue by Type (2016-2026)
8.2 Asia-Pacific Myasthenia Gravis Therapies Revenue by Application (2016-2026)
8.3 Asia-Pacific Myasthenia Gravis Therapies Market Size by Region
8.3.1 Asia-Pacific Myasthenia Gravis Therapies Revenue by Region (2016-2026)
8.3.2 China Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
8.3.3 Japan Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
8.3.4 South Korea Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
8.3.5 India Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
8.3.7 Australia Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Myasthenia Gravis Therapies Revenue by Type (2016-2026)
9.2 South America Myasthenia Gravis Therapies Revenue by Application (2016-2026)
9.3 South America Myasthenia Gravis Therapies Market Size by Country
9.3.1 South America Myasthenia Gravis Therapies Revenue by Country (2016-2026)
9.3.2 Brazil Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
9.3.3 Argentina Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Myasthenia Gravis Therapies Revenue by Type (2016-2026)
10.2 Middle East & Africa Myasthenia Gravis Therapies Revenue by Application (2016-2026)
10.3 Middle East & Africa Myasthenia Gravis Therapies Market Size by Country
10.3.1 Middle East & Africa Myasthenia Gravis Therapies Revenue by Country (2016-2026)
10.3.2 Turkey Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
10.3.4 UAE Myasthenia Gravis Therapies Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Myasthenia Gravis Therapies Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Myasthenia Gravis Therapies Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Myasthenia Gravis Therapies Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Myasthenia Gravis Therapies Revenue (USD Million) by Region (2016-2021)
Table 5. Global Myasthenia Gravis Therapies Revenue Market Share by Region (2021-2026)
Table 6. Alexion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Alexion Pharmaceuticals Major Business
Table 8. Alexion Pharmaceuticals Myasthenia Gravis Therapies Product and Solutions
Table 9. Alexion Pharmaceuticals Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Myasthenia Gravis Therapies Product and Solutions
Table 13. Novartis Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. CSL Behring Corporate Information, Head Office, and Major Competitors
Table 15. CSL Behring Major Business
Table 16. CSL Behring Myasthenia Gravis Therapies Product and Solutions
Table 17. CSL Behring Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Grifols Corporate Information, Head Office, and Major Competitors
Table 19. Grifols Major Business
Table 20. Grifols Myasthenia Gravis Therapies Product and Solutions
Table 21. Grifols Myasthenia Gravis Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Global Myasthenia Gravis Therapies Revenue (USD Million) by Players (2019-2021)
Table 23. Global Myasthenia Gravis Therapies Revenue Share by Players (2019-2021)
Table 24. Breakdown of Myasthenia Gravis Therapies by Company Type (Tier 1, Tier 2 and Tier 3)
Table 25. Myasthenia Gravis Therapies Players Head Office, Products and Services Provided
Table 26. Myasthenia Gravis Therapies Mergers & Acquisitions in the Past Five Years
Table 27. Myasthenia Gravis Therapies New Entrants and Expansion Plans
Table 28. Global Myasthenia Gravis Therapies Revenue (USD Million) by Type (2016-2021)
Table 29. Global Myasthenia Gravis Therapies Revenue Share by Type (2016-2021)
Table 30. Global Myasthenia Gravis Therapies Revenue Forecast by Type (2021-2026)
Table 31. Global Myasthenia Gravis Therapies Revenue by Application (2016-2021)
Table 32. Global Myasthenia Gravis Therapies Revenue Forecast by Application (2021-2026)
Table 33. North America Myasthenia Gravis Therapies Revenue by Type (2016-2021) & (USD Million)
Table 34. North America Myasthenia Gravis Therapies Revenue by Type (2021-2026) & (USD Million)
Table 35. North America Myasthenia Gravis Therapies Revenue by Application (2016-2021) & (USD Million)
Table 36. North America Myasthenia Gravis Therapies Revenue by Application (2021-2026) & (USD Million)
Table 37. North America Myasthenia Gravis Therapies Revenue by Country (2016-2021) & (USD Million)
Table 38. North America Myasthenia Gravis Therapies Revenue by Country (2021-2026) & (USD Million)
Table 39. Europe Myasthenia Gravis Therapies Revenue by Type (2016-2021) & (USD Million)
Table 40. Europe Myasthenia Gravis Therapies Revenue by Type (2021-2026) & (USD Million)
Table 41. Europe Myasthenia Gravis Therapies Revenue by Application (2016-2021) & (USD Million)
Table 42. Europe Myasthenia Gravis Therapies Revenue by Application (2021-2026) & (USD Million)
Table 43. Europe Myasthenia Gravis Therapies Revenue by Country (2016-2021) & (USD Million)
Table 44. Europe Myasthenia Gravis Therapies Revenue by Country (2021-2026) & (USD Million)
Table 45. Asia-Pacific Myasthenia Gravis Therapies Revenue by Type (2016-2021) & (USD Million)
Table 46. Asia-Pacific Myasthenia Gravis Therapies Revenue by Type (2021-2026) & (USD Million)
Table 47. Asia-Pacific Myasthenia Gravis Therapies Revenue by Application (2016-2021) & (USD Million)
Table 48. Asia-Pacific Myasthenia Gravis Therapies Revenue by Application (2021-2026) & (USD Million)
Table 49. Asia-Pacific Myasthenia Gravis Therapies Revenue by Region (2016-2021) & (USD Million)
Table 50. Asia-Pacific Myasthenia Gravis Therapies Revenue by Region (2021-2026) & (USD Million)
Table 51. South America Myasthenia Gravis Therapies Revenue by Type (2016-2021) & (USD Million)
Table 52. South America Myasthenia Gravis Therapies Revenue by Type (2021-2026) & (USD Million)
Table 53. South America Myasthenia Gravis Therapies Revenue by Application (2016-2021) & (USD Million)
Table 54. South America Myasthenia Gravis Therapies Revenue by Application (2021-2026) & (USD Million)
Table 55. South America Myasthenia Gravis Therapies Revenue by Country (2016-2021) & (USD Million)
Table 56. South America Myasthenia Gravis Therapies Revenue by Country (2021-2026) & (USD Million)
Table 57. Middle East & Africa Myasthenia Gravis Therapies Revenue by Type (2016-2021) & (USD Million)
Table 58. Middle East & Africa Myasthenia Gravis Therapies Revenue by Type (2021-2026) & (USD Million)
Table 59. Middle East & Africa Myasthenia Gravis Therapies Revenue by Application (2016-2021) & (USD Million)
Table 60. Middle East & Africa Myasthenia Gravis Therapies Revenue by Application (2021-2026) & (USD Million)
Table 61. Middle East & Africa Myasthenia Gravis Therapies Revenue by Country (2016-2021) & (USD Million)
Table 62. Middle East & Africa Myasthenia Gravis Therapies Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Myasthenia Gravis Therapies Picture
Figure 2. Global Myasthenia Gravis Therapies Revenue Market Share by Type in 2020
Figure 3. Ocular Myasthenia Gravis
Figure 4. Congenital Myasthenia Gravis
Figure 5. Generalized Myasthenia Gravis
Figure 6. Transient Myasthenia Gravis
Figure 7. Others
Figure 8. Myasthenia Gravis Therapies Revenue Market Share by Application in 2020
Figure 9. Hospitals and Clinics Picture
Figure 10. Diagnostic Centers Picture
Figure 11. Academic and Research Organizations Picture
Figure 12. Global Myasthenia Gravis Therapies Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Myasthenia Gravis Therapies Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Myasthenia Gravis Therapies Revenue Market Share by Region (2016-2026)
Figure 15. Global Myasthenia Gravis Therapies Revenue Market Share by Region in 2020
Figure 16. North America Myasthenia Gravis Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Myasthenia Gravis Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Myasthenia Gravis Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Myasthenia Gravis Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Myasthenia Gravis Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Myasthenia Gravis Therapies Market Drivers
Figure 22. Myasthenia Gravis Therapies Market Restraints
Figure 23. Myasthenia Gravis Therapies Market Trends
Figure 24. Alexion Pharmaceuticals Recent Developments and Future Plans
Figure 25. Novartis Recent Developments and Future Plans
Figure 26. CSL Behring Recent Developments and Future Plans
Figure 27. Grifols Recent Developments and Future Plans
Figure 28. Global Myasthenia Gravis Therapies Revenue Share by Players in 2020
Figure 29. Myasthenia Gravis Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 30. Global Top 3 Players Myasthenia Gravis Therapies Revenue Market Share in 2020
Figure 31. Global Top 10 Players Myasthenia Gravis Therapies Revenue Market Share in 2020
Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 33. Global Myasthenia Gravis Therapies Revenue Share by Type in 2020
Figure 34. Global Myasthenia Gravis Therapies Market Share Forecast by Type (2021-2026)
Figure 35. Global Myasthenia Gravis Therapies Revenue Share by Application in 2020
Figure 36. Global Myasthenia Gravis Therapies Market Share Forecast by Application (2021-2026)
Figure 37. North America Myasthenia Gravis Therapies Sales Market Share by Type (2016-2026)
Figure 38. North America Myasthenia Gravis Therapies Sales Market Share by Application (2016-2026)
Figure 39. North America Myasthenia Gravis Therapies Revenue Market Share by Country (2016-2026)
Figure 40. United States Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Myasthenia Gravis Therapies Sales Market Share by Type (2016-2026)
Figure 44. Europe Myasthenia Gravis Therapies Sales Market Share by Application (2016-2026)
Figure 45. Europe Myasthenia Gravis Therapies Revenue Market Share by Country (2016-2026)
Figure 46. Germany Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. France Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. United Kingdom Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Russia Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Italy Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Myasthenia Gravis Therapies Sales Market Share by Type (2016-2026)
Figure 52. Asia-Pacific Myasthenia Gravis Therapies Sales Market Share by Application (2016-2026)
Figure 53. Asia-Pacific Myasthenia Gravis Therapies Revenue Market Share by Region (2016-2026)
Figure 54. China Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Japan Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. South Korea Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. India Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Southeast Asia Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Australia Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South America Myasthenia Gravis Therapies Sales Market Share by Type (2016-2026)
Figure 61. South America Myasthenia Gravis Therapies Sales Market Share by Application (2016-2026)
Figure 62. South America Myasthenia Gravis Therapies Revenue Market Share by Country (2016-2026)
Figure 63. Brazil Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Argentina Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Middle East and Africa Myasthenia Gravis Therapies Sales Market Share by Type (2016-2026)
Figure 66. Middle East and Africa Myasthenia Gravis Therapies Sales Market Share by Application (2016-2026)
Figure 67. Middle East and Africa Myasthenia Gravis Therapies Revenue Market Share by Country (2016-2026)
Figure 68. Turkey Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Saudi Arabia Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. UAE Myasthenia Gravis Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Methodology
Figure 72. Research Process and Data Source
Buy
